Accéder au contenu
Merck

Genomic occupancy of Runx2 with global expression profiling identifies a novel dimension to control of osteoblastogenesis.

Genome biology (2014-03-25)
Hai Wu, Troy W Whitfield, Jonathan A R Gordon, Jason R Dobson, Phillip W L Tai, Andre J van Wijnen, Janet L Stein, Gary S Stein, Jane B Lian
RÉSUMÉ

Osteogenesis is a highly regulated developmental process and continues during the turnover and repair of mature bone. Runx2, the master regulator of osteoblastogenesis, directs a transcriptional program essential for bone formation through genetic and epigenetic mechanisms. While individual Runx2 gene targets have been identified, further insights into the broad spectrum of Runx2 functions required for osteogenesis are needed. By performing genome-wide characterization of Runx2 binding at the three major stages of osteoblast differentiation--proliferation, matrix deposition and mineralization--we identify Runx2-dependent regulatory networks driving bone formation. Using chromatin immunoprecipitation followed by high-throughput sequencing over the course of these stages, we identify approximately 80,000 significantly enriched regions of Runx2 binding throughout the mouse genome. These binding events exhibit distinct patterns during osteogenesis, and are associated with proximal promoters and also non-promoter regions: upstream, introns, exons, transcription termination site regions, and intergenic regions. These peaks were partitioned into clusters that are associated with genes in complex biological processes that support bone formation. Using Affymetrix expression profiling of differentiating osteoblasts depleted of Runx2, we identify novel Runx2 targets including Ezh2, a critical epigenetic regulator; Crabp2, a retinoic acid signaling component; Adamts4 and Tnfrsf19, two remodelers of the extracellular matrix. We demonstrate by luciferase assays that these novel biological targets are regulated by Runx2 occupancy at non-promoter regions. Our data establish that Runx2 interactions with chromatin across the genome reveal novel genes, pathways and transcriptional mechanisms that contribute to the regulation of osteoblastogenesis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
L-acide ascorbique, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L-acide ascorbique, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L-acide ascorbique, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L-acide ascorbique, reagent grade, crystalline
USP
Acide ascorbique, United States Pharmacopeia (USP) Reference Standard
Supelco
L-acide ascorbique, analytical standard
Sigma-Aldrich
L-acide ascorbique, reagent grade
Sigma-Aldrich
IgG de lapin normale, Normal Rabbit IgG Polyclonal Antibody control validated for use in Immunoprecipitation & Western Blotting.
Sigma-Aldrich
L-acide ascorbique, meets USP testing specifications
Sigma-Aldrich
L-acide ascorbique, 99%
Sigma-Aldrich
L-acide ascorbique, FCC, FG
Supelco
L-acide ascorbique, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-acide ascorbique, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
L-acide ascorbique, ACS reagent, ≥99%
Sigma-Aldrich
L-acide ascorbique, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
L-acide ascorbique, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-acide ascorbique, puriss. p.a., ≥99.0% (RT)
Sigma-Aldrich
L-acide ascorbique, tested according to Ph. Eur.
Supelco
L-acide ascorbique, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
MISSION® esiRNA, targeting human RUNX2
Sigma-Aldrich
ANTI-RUNX2 antibody produced in mouse, clone 6E1, purified immunoglobulin, buffered aqueous solution